- UroToday Home
- Transformative Evidence
Transformative Evidence
ENZAMET Trial: Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Curated by clinicians: educational forums with videos, abstracts and conference coverage
Videos
State of the industry video and audio conversations
August 19, 2019
June 5, 2019
Publications
Publications focusing on urologic malignancies and treatments
FDA Accepts sNDA Filing and Grants Priority Review for Advanced Prostate Cancer Medication
San Francisco, CA USA (UroToday.com) -- Astellas Pharma Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI®(enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). Read More
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
BACKGROUND: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer. Read More
Conference Coverage
Recent data from conferences worldwide
ASCO GU 2020: Best of Journals Prostate Cancer: Medical Oncology
Presented by Alicia Morgans, MD, MPH
San Francisco, California (UroToday.com) Dr. Alicia Morgans, Associate Professor and Medical Oncologist at Northwestern University Feinberg School of Medicine, presented some of the most influential articles from the past year in the field of prostate cancer research from a medical oncology perspective. Read More
ESMO 2019: Invited Discussant: Patient Reported Outcomes in Metastatic Hormone-Naïve Prostate Cancer and Who to Give Primary Radiotherapy To?
Presented by Henrik Gronberg, MD, PhD
Barcelona, Spain (UroToday.com) At the prostate cancer poster discussion at ESMO 2019, Dr. Henrik Gronberg provided a discussion of three important abstracts: the updated STAMPEDE “M1|RT Comparison”, as well as patient reported outcomes from both ENZAMET and TITAN. Read More
ESMO 2019: Health-Related Quality of Life in a Randomized Phase 3 Trial of Enzalutamide with Standard First Line Therapy for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET, ANZUP-led, International, Co-Operative Group Trial
Presented by Martin R. Stockler, MBBS(Hons) MSc(Clin Epi) FRACP
Barcelona, Spain (UroToday.com) At 2019 ASCO meeting, Davis and colleagues previously reported that treatment with enzalutamide rather than an older non-steroidal anti-androgen (bicalutamide, nilutamide, or flutamide), resulted in longer overall survival Read More
ASCO 2019: Intensified Up-Front Therapy for Prostate Cancer: The Revolution Continues with ENZAMET
Presented by Tanya B. Dorff, MD
Chicago, IL (UroToday.com) The presentation of ENZAMET, overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial, by Christopher Sweeney, MBBS, was followed by Tanya B. Dorff, MD, of City of Hope Cancer Center, Read More
ASCO 2019: Overall Survival Results of a Phase III Randomized Trial of Standard-of-Care Therapy with or without Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET, an ANZUP-led International Cooperative Group Trial
Presented by Christopher Sweeney, MBBS
Chicago, IL (UroToday.com) Abiraterone and docetaxel are both standard of care options for available for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the United States. Read More
ASCO 2019: ENZAMET, Overall Survival Results of a Phase III Randomized Trial of Standard-of-care Therapy with or without Enzalutamide for mHSPC, an ANZUP-led International Cooperative Group Trial
Presented by Christopher Sweeney, MBBS
Chicago, IL (UroToday.com) Testosterone suppression is the backbone of treatment for metastatic hormone-sensitive prostate cancer (mHSPC), however, until 2014, testosterone suppression +/- standard nonsteroidal antiandrogen was the only therapy available. Read More